More on MRD... Dr. W. Wierda, MDAnderson - CLL Support
More on MRD... Dr. W. Wierda, MDAnderson
You need to be a member of this community to see this post.
Read more about...
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Use of MRD Status Following Obinutuzumab/Ibrutinib to Guide Subsequent Intensification of Therapy in CLL
August 6, 2019
In this 2-part, single-arm, open-label, multicenter trial (Clinical Trials.gov...
Dr. John Allan - Chronic Lymphocytic Leukemia (CLL) Patients @Undetectable Measurable Residual Disease (MRD) after Ibrutinib Plus Venetoclax
ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with...
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Update on The CLARITY Study
Published on line July 11, 2019, Accepted by JCO May 31 2019
Dr P Hillmen
We have some members who...
Dr. Shadman on Fixed Durations of Treatment in CLL
Mazyar Shadman, MD, MPH
Published: Monday, Jul 08, 2019
Mazyar Shadman, MD, MPH, assistant member,...
“MRD: What Should It Mean to Me?” Ever dreamed of coming to a point where your CLL treatment could be safely stopped? View CLL Webinar.
Instant replay! In case you missed it, here it is! CLL Society’s latest Webinar — “MRD: What Should...
Related Posts
- Can Venetoclax/Obinituzimab reduce the risk of additional somatic mutations? - Not necessarily. The BTK inhibitors are excellent at....
Acalabrutinib Plus Venetoclax and Obinutuzumab Achieves High Bone Marrow uMRD Rate in Chronic Lymphocytic Leukemia - CLL
Response and Survival Rates for FCR and Ibrutinib- Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
- Dr. Wierda on the Importance of Clinical Trials
